Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2038097

Fc1cccc(-c2c(CNc3ncnc4[nH]cnc34)cc(Cl)c3ccnnc23)c1.O=C(O)C(F)(F)F

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.49
BCL2 P10415 1/20 0.44
AURKA O14965 8/20 0.35
RPS6KB1 P23443 7/20 0.35
AURKB Q96GD4 5/20 0.35
PTGER2 P43116 4/20 0.33
MAP4K4 O95819 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
PRKD3 O94806 1/20 0.33
PAK4 O96013 1/20 0.33
ABL1 P00519 1/20 0.33
LCK P06239 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
PDGFRB P09619 1/20 0.33
FGFR1 P11362 1/20 0.33
PRKACA P17612 1/20 0.33
FLT1 P17948 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2012713 0.93 PIK3CD (0.55) PIK3CDBCL2AURKARPS6KB1AURKB
SCHEMBL2016865 0.85 PIK3CD (0.56) PIK3CDBCL2AURKAAURKBMAP4K4
SCHEMBL2051059 0.83 PIK3CD (0.53) PIK3CDBCL2AURKAAURKBMAP4K4
Trifluoroacetic Acid SCHEMBL2050998 0.83 PIK3CD (0.40) PIK3CDBCL2
Trifluoroacetic Acid SCHEMBL2013841 0.80 BCL2 (0.42) PIK3CDBCL2LRRK2NR1H2
SCHEMBL2038100 0.80 PIK3CD (0.41) PIK3CDBCL2AURKARPS6KB1AURKB
Trifluoroacetic Acid SCHEMBL2012078 0.79 BCL2 (0.41) PIK3CDBCL2LRRK2NR1H2
Trifluoroacetic Acid SCHEMBL2052496 0.78 PIK3CD (0.35) PIK3CDRPS6KB1
SCHEMBL2012486 0.77 PIK3CD (0.46) PIK3CDBCL2
SCHEMBL2016719 0.77 PIK3CD (0.47) PIK3CDBCL2AURKARPS6KB1AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 PIK3CD 13/4885BCL2 1174/4885AURKA 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.